

PACAP biochemical

PACAP (6-38), human, ovine, rat acetate

CATALOG #
AAA229053


PRODUCT SYNONYMS

PACAP; PACAP (6-38); human; ovine; rat acetate; PACAP biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	99.84%
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	Intravesical administration of PACAP (6-38)(300 nM) significantly ($p \leq 0.01$) increases intercontraction interval (2.0-fold) and void volume (2.5-fold) in NGF-OE mice. Intravesical instillation of PACAP (6-38) also decreases baseline bladder pressure in NGF-OE mice. Intravesical administration of PACAP (6-38)(300 nM) significantly ($p \leq 0.01$) reduces pelvic sensitivity in NGF-OE mice but is without effect in WT mice[3].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
WAY-118959-A, CAS 315703-81-2



Structure
WAY-118959-A, CAS 315703-81-2

ADDITIONAL INFORMATION

Related Product Information for PACAP biochemical	PACAP (6-38), human, ovine, rat acetate is a potent PACAP receptor antagonist with IC50s of 30, 600, and 40 nM for PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2, respectively.
Product Categories/Family for PACAP biochemical	Cytoskeletal Signaling; Others

NCBI AND UNIPROT INFORMATION

Molecular Weight	342.44
------------------	--------

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.